The number of patients is growing, and so is the need to find a cure Anestimated50 million people were living with dementia and Alzheimer’s disease last year. Every 20 years this number is expected to double, affecting an estimated 75 million by 2030. Presently 5.7 million Americans are li...
The article reports on the seed grants provided by the Brookdale Foundation's National Group Respite Program in the U.S. to organizations to develop and implement social model group respite programs for patients with Alzheimer's disease or related dementia....
As specified in the prescribing information, Leqembi is indicated for the treatment of Alzheimer's disease. The labeling states that treatment with Leqembi should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was studied ...
The Clarity AD Phase 3 clinical study for lecanemab in early AD is ongoing and Eisai completed enrollment in March 2021 with 1,795 patients. The readout of the primary endpoint data of Clarity AD will occur in the Fall of 2022. The FDA has agreed that the results o...
For secondary outcomes, the distribution of patients across mRS categories demonstrated good function outcomes for those in the study drug group; however, there were no other effects on the prespecified secondary outcomes.3 In terms of safety, 89.8% of those in the edaravone dexborneol ...
The efficacy of ADUHELM was evaluated in two Phase 3 clinical trials—EMERGE (Study 1) and ENGAGE (Study 2)—in patients with early stages of Alzheimer’s disease (mild cognitive impairment and mild dementia) wi...
The efficacy of ADUHELM was evaluated in two Phase 3 clinical trials—EMERGE (Study 1) and ENGAGE (Study 2)—in patients with early stages of Alzheimer’s disease (mild cognitive impairment and mild dementia) with confirmed presence of amyloid pathology. The effects of ADUHELM were also assessed...
dementia and other life-threatening diseases. Vivos’ oral appliances address the dental tissue anomalies and malformations known to be associated with OSA. Unlike current standard-of-care interventions, patients treated with the Vivos System typically complete their therapy in 12 to 24 mont...
Yale School of Medicine will use its research grant to develop care planning tools to improve mental health outcomes for caregivers and seniors with dementia. Terri R Fried, MD, will test whether group visits to address care planning positively impact caregivers’ and patients’ sen...
“For instance, we share our own expertise from different disciplines and different points of view, which can result in a new strategy or approach that can address the health equity among long-term care residents with ADRD [dementia].” ...